ArriVent BioPharma Stock Climbs on Early Data for GI Cancer Drug
ArriVent BioPharma shares rose premarket after early Phase 1 results for ARR-217 in gastrointestinal cancers, Dow Jones Newswires reported.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
ArriVent BioPharma shares jumped 9.3% to $22.95 in Monday premarket trading after the biotech reported encouraging initial Phase 1 findings for its gastrointestinal cancer therapy, according to Dow Jones Newswires. The stock had gained 4.4% year to date at the latest market close.
The drug conjugate ARR-217 showed strong tumor-fighting activity across several dose levels, the company said. At 6 mg in pretreated colorectal patients, the objective response rate reached 45% and disease control reached 93%. At 4 mg and above, the figures were 34% and 92%. Developed with Lepu Biopharma, the drug now moves into Phase 1b at 5 and 6 mg, with further dose-optimization data expected in 2027.
why it matters
The results matter mainly to investors in small biotech companies, where early trial readouts often move share prices sharply. Because these are Phase 1 data, the next clear checkpoint will be the dose-optimization update the company expects in 2027.
market impact
ArriVent BioPharma shares: positive early ARR-217 data supports investor interest in the stock.
tags
instruments
sources
- ArriVent BioPharma Shares Gain on Study Data for Gastrointestinal Cancer Treatment — Dow Jones Newswires, 26 October 2026 at 11:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗